PT - JOURNAL ARTICLE AU - Almarzooq, Ammar Ali TI - Exploration of interethnic variation and repurposed drug efficacy in the treatment of SARS-CoV-2 Infection (COVID-19) AID - 10.1101/2021.03.07.21253095 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.07.21253095 4099 - http://medrxiv.org/content/early/2021/03/08/2021.03.07.21253095.short 4100 - http://medrxiv.org/content/early/2021/03/08/2021.03.07.21253095.full AB - The COVID-19 global pandemic has led to repurposing of drugs, with little underlying evidence for treatment safety and efficacy. This may increase complications for patients with acute viral respiratory infections. UGT1A1 and CYP2D6 enzymes are involved in the metabolism of atazanavir and fluvoxamine repurposed for COVID-19. This study aimed to elucidate the role of interethnic variation in these enzymes in the efficacy of repurposed drug therapies. A retrospective cohort of 101 Jordanian Arab samples were genotyped using Affymetrix DMET Plus Premier Package. Comprehensive global population genetic structure analyses were performed for CYP2D6 and UGT1A1 allele frequencies across multi-ethnic populations of over 131,000 global subjects from 417 published reports, revealing that Jordanian Arabs share the closest sequence homology to European and Near East populations. The East Asian populations have significantly over-representaiton of individuals with diplotype pairs for reduced atazanavir metabolism compared to the African populations and are more likely to show impaired UGT1A1 metabolism. East Asian populations are also 4.4x more likely to show impaired fluvoxamine metabolism than South Central Asian and Oceanian populations, and 8x more likely than other ancestry populations. The results here support previous findings that interethnic variation should be used for developing proper population-specific dosage guidelines.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding declared.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Signed informed consent was obtained from all participants recruited for this study under the ethical approval from University Review Committee for Research on Humans at Jordan University of Science and Technology (JUST) registered under [67/2/2013] on 4/7/2013, and performed in accordance with the principles enshrined in the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during the current study are included in the supplementary files. Publicly available repositories used in the analyses were previously published under PMID: 26417955 and 25974703. https://api.pharmgkb.org/v1/download/file/attachment/UGT1A1_frequency_table.xlsx https://api.pharmgkb.org/v1/download/file/attachment/CYP2D6_frequency_table.xlsx